 |
|
|
| |
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis
|
| |
| |
Reported by Jules Levin
18th International Workshop on Clinical Pharmacology of Antiviral Therapy
Chicago, IL
Kimberly Adkison,1 Lesley Kahl,1 Elizabeth Blair,1 Kostas Angelis,2 Herta Crauwels,3 Maria Nascimento,1 Michael Aboud1
1ViiV Healthcare; 2GlaxoSmithKline; 3Janssen Pharmaceutica
CROI: SWORD 1 & 2: Switch to DTG + RPV Maintains Virologic Suppression Through 48 Weeks, a Phase III Study - (02/16/17)
C0, pre-dose plasma concentration; DTG, dolutegravir; EFV, efavirenz; NNRTI,
non-nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PA-IC90, protein-adjusted 90% inhibitory concentration; PK, pharmacokinetic; RPV, rilpivirine
|
| |
|
|
|
|
|
